Tewalt Eric F, Maynard Jason C, Walters Julie Jo, Schell Amanda M, Berwin Brent L, Nicchitta Christopher V, Norbury Christopher C
Department of Microbiology and Immunology, Milton S. Hershey College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA.
Immunology. 2008 Dec;125(4):480-91. doi: 10.1111/j.1365-2567.2008.02861.x. Epub 2008 May 15.
CD8(+) T cells (T(CD8+)) differentiate into effector cells following recognition of specific peptide-major histocompatibility complex (MHC) class I complexes (pMHC-I) on the surface of professional APCs (pAPCs), such as dendritic cells. Antigenic pMHC-I can be generated from two spatially distinct sources. The direct presentation pathway involves generation of peptide from protein substrate synthesized within the cell that is presenting the pMHC-I. Alternatively, the cross presentation pathway involves presentation of antigen that is not synthesized within the presenting cell, but is derived from exogenous proteins synthesized within other donor cells. The mechanisms by which cross presentation of exogenous antigens occur in vivo remain controversial. The C-type lectin scavenger receptor A (SR-A) has been implicated in a number of potential cross presentation pathways, including the presentation of peptide bound to heat shock proteins, such as glycoprotein 96 (gp96), and the transfer of pMHC-I from a donor cell to the pAPC. We demonstrate here that initiation of T(CD8+) responses is normal in mice lacking SR-A, and that the redundancy of ligand binding exhibited by the SR family is likely to be an important mechanism that ensures cross presentation in vivo. These observations emphasize the requirement to target multiple receptors and antigen-processing pathways during the rational design of vaccines aimed at eliciting protective T(CD8+).
CD8(+) T细胞(T(CD8+))在识别专职抗原呈递细胞(pAPC)(如树突状细胞)表面的特异性肽 - 主要组织相容性复合体(MHC)I类复合体(pMHC-I)后分化为效应细胞。抗原性pMHC-I可从两个空间上不同的来源产生。直接呈递途径涉及从呈递pMHC-I的细胞内合成的蛋白质底物产生肽。另外,交叉呈递途径涉及呈递细胞内未合成但源自其他供体细胞内合成的外源蛋白质的抗原呈递。体内外源抗原交叉呈递发生的机制仍存在争议。C型凝集素清道夫受体A(SR-A)已涉及许多潜在的交叉呈递途径,包括与热休克蛋白(如糖蛋白96(gp96))结合的肽的呈递,以及pMHC-I从供体细胞向pAPC的转移。我们在此证明,缺乏SR-A的小鼠中T(CD8+)反应的起始是正常的,并且SR家族表现出的配体结合冗余可能是确保体内交叉呈递的重要机制。这些观察结果强调了在合理设计旨在引发保护性T(CD8+)的疫苗时靶向多个受体和抗原加工途径的必要性。